Spasm: Clinical Trials

27 trials for Spasm, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed, 7 terminated, 3 unknown, 1 recruiting. 27 Phase 2, 3 Phase 3, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 227Completed 16, Terminated 7, Unknown 3, Recruiting 1
Phase 33Completed 2, Unknown 1
Phase 12Completed 2

Follow Spasm: new trials by email Literature Review of Spasm trials Research Report on Spasm

Trials (filtered) newest first · largest first

All 27 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)
Guanfacine Hydrochloride Immediate Release, Placebo - Hyperactivity in Children With Down Syndrome, Impulsivity in Children With Down Syndrome
Phase 2TerminatedRachel G. Greenberg, MD, MB, MHS32024-12-092026-04-17
Treatment With Cannabis Oil Containing CBD, THC, CBDV or CBG vs. Placebo of Persons With ADHD
Cannabis oil - ADHD, Hyperactivity
Phase 2TerminatedBrlev Agricultural Crops Ltd82022-07-312023-04-25
Use of Corticosteroids in Third Molar Surgery
Dexamethasone 4 Mg/mL Injectable Solution, MethylPREDNISolone 40 Mg/mL Injectable Suspension - Inflammation, Pain, Postoperative
Phase 2 / Phase 3CompletedUniversidad de Granada842022-01-152023-12-06
Web-Based Program in Helping Patients With Head and Neck Cancer Adhere to Swallowing Exercises and Coping Strategies
Internet-Based Intervention, Quality-of-Life Assessment, Questionnaire Administration - Throat Carcinoma
Phase 2RecruitingM.D. Anderson Cancer Center3002019-03-182026-10-06
Tolperisone in Acute Muscle Spasm of the Back
Tolperisone, Placebo - Back Pain, Acute Pain
Phase 2CompletedNeurana Pharmaceuticals, Inc.4152019-02-012022-02-01
Effectiveness of Light-emitting Diode (LED) Photobiomodulation in the Extraction of Retained Lower Third Molars
LED group, Sham group - Pain, Postoperative, Edema
Phase 2UnknownUniversity of Nove de Julho342018-09-012018-10-11
Wumeiwan Jiawei Fang Use in Patients With Blepharospasm
Wumeiwan Jiawei Fang, botulinum toxin A - Dry Eye Syndromes, Meige Syndrome
Phase 2 / Phase 3UnknownChina Academy of Chinese Medical Sciences802018-01-122022-11-17
A Phase 2 Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)
Radiprodil - Infantile Spasms (IS)
Phase 2TerminatedUCB Biopharma S.P.R.L.32017-12-042019-09-17
A Study to Assess the Safety and Effectiveness of FLX-787 in Subjects With Charcot-Marie-Tooth Disease Experiencing Muscle Cramps.
FLX-787-ODT (orally disintegrating tablet), Placebo ODT - Charcot-Marie-Tooth Disease
Phase 2TerminatedFlex Pharma, Inc.272017-10-162018-08-29
A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.
FLX-787-ODT (orally disintegrating tablet), Placebo ODT - Motor Neuron Disease
Phase 2TerminatedFlex Pharma, Inc.542017-07-282018-08-29
Vaginal Diazepam for the Treatment of Female Pelvic Pain
Diazepam, Placebo - Pelvic Floor Disorders, Pelvic Pain
Phase 2CompletedRaymond Foster502013-09-012024-09-03
Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome
Kyodophilus multi-strain probiotic capsules, Kyodophilus Matching Placebo Capsules - Irritable Bowel Syndrome, Digestive System Diseases
Phase 1 / Phase 2CompletedThe Canadian College of Naturopathic Medicine1002013-06-012015-03-17
Trismus Trial of Therabite vs Wooden Spatula in Head and Neck Cancer Patients
Wooden spatula, Therabite - Oropharyngeal Cancer, Oral Cancer
Phase 2CompletedBrynn Chappell712012-12-012015-10-01
Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder
Omega-3 Fatty Acids, Placebo - Autism Spectrum Disorders, Hyperactivity
Phase 2CompletedHugo W. Moser Research Institute at Kennedy Krieger, Inc.572012-09-012020-08-31
Effect on Tear Functions of Pretarsal and Preseptal Techniques of Botulinum Toxin Type A Injection in Hemifacial Spasm
preseptal injection of botulinum toxin type A, pretarsal injection of Botulinum toxin type A - Hemifacial Spasm
Phase 2UnknownKhon Kaen University262012-04-012012-03-28
Proof-of-Concept, Calcium Aluminosilicate Anti-Diarrheal (CASAD) for Treatment of Clostridium Difficile Infection
Calcium Aluminosilicate Anti-Diarrheal (CASAD) - Diarrhoea, Clostridium Difficile
Phase 2TerminatedSalient Pharmaceuticals Incorporated22012-03-012013-03-08
Classroom-based Distance Intervention for Teachers of Children With Attention Deficit Hyperactivity Disorder
Teacher Help for ADHD - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 2CompletedDalhousie University1162012-02-012014-03-28
Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X Syndrome
Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E), Placebo - Fragile X Syndrome
Phase 2CompletedYolanda de Diego Otero302010-12-012015-04-14
Topical Radial Artery Vasodilation
Nitroglycerin and lidocaine, Placebo - Cardiac Catheterization, Spasm
Phase 2 / Phase 3CompletedUniversity of California, San Francisco862010-07-012018-09-25
Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome (IBS)
Kyodophilus multi-strain probiotic capsules, Kyodophilus Matching Placebo Capsules - Irritable Bowel Syndrome, Digestive System Diseases
Phase 1 / Phase 2CompletedThe Canadian College of Naturopathic Medicine1282010-05-012011-04-01

Showing 20 of 27. Sign in to see all of them.

Narrower conditions

Attention Deficit Disorder with Hyperactivity (7)  ·  Trismus (5)  ·  Impulsive Behavior (4)  ·  Diarrhea (3)  ·  Muscle Cramp (3)  ·  Anxiety Disorders (2)  ·  Blepharospasm (2)  ·  Colonic Diseases, Functional (2)  ·  Constipation (2)  ·  Digestive System Diseases (2)  ·  Head and Neck Neoplasms (2)  ·  Irritable Bowel Syndrome (2)  ·  Mouth Neoplasms (2)  ·  Mucopolysaccharidosis IV (2)

Broader conditions

Neurologic Manifestations (27)  ·  Neuromuscular Manifestations (27)  ·  Pathological Conditions, Signs and Symptoms (27)  ·  Signs and Symptoms (27)  ·  Nervous System Diseases (25)  ·  Mental Disorders (9)  ·  Neurodevelopmental Disorders (9)  ·  Attention Deficit and Disruptive Behavior Disorders (7)  ·  Behavior (5)  ·  Central Nervous System Diseases (4)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4)  ·  Genetic Diseases, Inborn (4)  ·  Pain (4)  ·  Metabolic Diseases (3)

Interventions

Botulinum Toxins, Type A (2)  ·  Amphetamine (1)  ·  Ascorbic Acid (1)  ·  Calcium Aluminosilicate (1)  ·  Dexamethasone (1)  ·  Diazepam (1)  ·  Docosahexaenoic Acids (1)  ·  Fatty Acids, Omega-3 (1)  ·  Guanfacine (1)  ·  Lidocaine (1)  ·  Methylprednisolone (1)  ·  Mexiletine (1)  ·  Nitroglycerin (1)  ·  Physical Therapy Modalities (1)  ·  Tolperisone (1)

Sponsors

Flex Pharma, Inc. (2)  ·  The Canadian College of Naturopathic Medicine (2)  ·  Brlev Agricultural Crops Ltd (1)  ·  Brynn Chappell (1)  ·  China Academy of Chinese Medical Sciences (1)  ·  Copenhagen University Hospital, Rigshospitalet (1)  ·  Dalhousie University (1)  ·  Enzymotec (1)  ·  Hugo W. Moser Research Institute at Kennedy Krieger, Inc. (1)  ·  Khon Kaen University (1)  ·  M.D. Anderson Cancer Center (1)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (1)  ·  Neurana Pharmaceuticals, Inc. (1)  ·  Otsuka Pharmaceutical Development & Commercialization, Inc. (1)  ·  Rachel G. Greenberg, MD, MB, MHS (1)

Countries

United States (12)  ·  Canada (4)  ·  Israel (3)  ·  Spain (2)  ·  Brazil (1)  ·  China (1)  ·  Denmark (1)  ·  France (1)  ·  Thailand (1)  ·  United Kingdom (1)

Top investigators

Dugald Seely, ND (2)  ·  Aarthi Narasimhan, MD (1)  ·  Abraham Weizman, MD (1)  ·  Andrew Boyle, MBBS, PhD (1)  ·  Bjorn Oskarsson, MD (1)  ·  David V Herin, Ph.D (1)  ·  Dr. Michael Lyon (1)  ·  Eileen H Shinn (1)  ·  Lucia M Perez Costillas, MD PhD (1)  ·  Mati Berkovitch (1)  ·  Nachum Vaisman, MD (1)  ·  Nezihe Elik, PhD (1)  ·  Nicolas Johnson, MD (1)  ·  Paul A Law, M.D. (1)

Results publications

PMID 18469236, PMID 21807480, PMID 23582415, PMID 24839884, PMID 25187257, PMID 25229260, PMID 25733754, PMID 28576350, PMID 29280763, PMID 29526341, PMID 29602860, PMID 8501266

NIH funding

2009 (1), 2016 (1), P50DA009262 (1)